Xilio Therapeutics, Inc. (XLO)

NASDAQ: XLO · IEX Real-Time Price · USD
2.23
-0.05 (-2.19%)
Dec 7, 2022 4:00 PM EST - Market closed
-2.19%
Market Cap 62.64M
Revenue (ttm) n/a
Net Income (ttm) -85.46M
Shares Out 27.40M
EPS (ttm) -6.56
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 25,530
Open 2.25
Previous Close 2.28
Day's Range 2.11 - 2.74
52-Week Range 2.01 - 16.93
Beta n/a
Analysts Buy
Price Target 21.42 (+860.5%)
Earnings Date Dec 1, 2022

About XLO

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until c... [Read more]

Industry Biotechnology
IPO Date Oct 22, 2021
Employees 74
Stock Exchange NASDAQ
Ticker Symbol XLO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for XLO stock is "Buy." The 12-month stock price forecast is 21.42, which is an increase of 860.54% from the latest price.

Price Target
$21.42
(860.54% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

WALTHAM, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, toda...

2 weeks ago - GlobeNewsWire

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

XTX202, a tumor-activated IL‑2, successfully reached target dose range of 1 mg/kg in ongoing Phase 1 clinical trial; preliminary evidence of increased CD8+ effector T cells and NK cells observed with no...

4 weeks ago - GlobeNewsWire

Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit

WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, toda...

1 month ago - GlobeNewsWire

Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference

WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, tod...

2 months ago - GlobeNewsWire

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor John Maraganore, Ph.D., former founding CEO of Alnylam Pharmaceuticals, Joins as a Strategic Advisor

2 months ago - GlobeNewsWire

Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, tod...

3 months ago - GlobeNewsWire

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-...

XTX101, tumor-selective anti-CTLA-4, has successfully reached dose levels exceeding the target dose with limited active (unmasked) molecule in the periphery in ongoing Phase 1 clinical trial

3 months ago - GlobeNewsWire

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

Paul Clancy Elected as Chair of the Board of Directors

5 months ago - GlobeNewsWire

Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference

WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today...

6 months ago - GlobeNewsWire

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

Clinical programs for XTX202, a tumor-selective IL-2, and XTX101, a tumor-selective anti-CTLA-4, continue to advance with preliminary data anticipated in 2022

6 months ago - GlobeNewsWire

Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, tod...

8 months ago - GlobeNewsWire

Xilio Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

Initial Phase 1 Data Readouts from Clinical Trials of XTX101 and XTX202 Anticipated in 2022

9 months ago - GlobeNewsWire

Xilio Therapeutics to Participate in the Cowen 42nd Annual Healthcare Conference

WALTHAM, Mass., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, toda...

9 months ago - GlobeNewsWire

Xilio Therapeutics to Participate in the Guggenheim 4th Annual Oncology Day

WALTHAM, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, toda...

10 months ago - GlobeNewsWire

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of ...

WALTHAM, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, toda...

10 months ago - GlobeNewsWire

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

WALTHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, toda...

11 months ago - GlobeNewsWire

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

Anticipate First Patient Dosing in Phase 1/2 Clinical Trial for XTX202, a Tumor-Selective IL-2, in First Quarter of 2022

1 year ago - GlobeNewsWire

Xilio Therapeutics Announces Closing of Initial Public Offering

WALTHAM, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced ...

1 year ago - GlobeNewsWire

Xilio Therapeutics Announces Pricing of Initial Public Offering

WALTHAM, Mass.--(BUSINESS WIRE)--Xilio Therapeutics Announces Pricing of Initial Public Offering.

1 year ago - Business Wire